Login / Signup

Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence.

Christopher N AndrewsRenata RehakMatthew WooIan WalkerChristopher MaNauzer ForbesKatherine RittenbachJoshua HathawayLynn WilsackAndy LiuYasmin NasserKeith A Sharkey
Published in: Alimentary pharmacology & therapeutics (2022)
Survey data suggest patients with CHS almost universally suffer from a cannabis use disorder, which has significant treatment implications. Treatment prevalence in the ED has increased substantially over a very short time period, with the highest rates seen during the Covid-19 pandemic.
Keyphrases
  • risk factors
  • healthcare
  • emergency department
  • mental health
  • machine learning
  • combination therapy
  • big data
  • deep learning
  • health information
  • data analysis